Comparing serum basal and follicular fluid levels of anti-Müllerian hormone as a predictor of in vitro fertilization outcomes in patients with and without polycystic ovary syndrome

Annals of Saudi Medicine

Volumn 30, Issue 6, 2010, Pages

  Arabzadeh, Somayeh ^a   Hossein, Ghamartaj ^a   Rashidi, Batool Hossein ^b   Hosseini, Marziyeh Agha ^c   Zeraati, Hojjat ^d  

^a UNIVERSITY OF TEHRAN   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

MUELLERIAN INHIBITING FACTOR;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; EMBRYO; EMBRYO DEVELOPMENT; ENZYME IMMUNOASSAY; FEMALE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; HUMAN; OOCYTE MATURATION; OOCYTE RETRIEVAL; OVARY FOLLICLE FLUID; OVARY POLYCYSTIC DISEASE; PREGNANCY RATE; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADULT; ANTI-MULLERIAN HORMONE; FEMALE; FERTILIZATION IN VITRO; FOLLICULAR FLUID; HUMANS; INFERTILITY, FEMALE; OOCYTES; POLYCYSTIC OVARY SYNDROME; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY RATE; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 78649386147     PISSN: 02564947     EISSN: 09754466     Source Type: Journal    
DOI: 10.4103/0256-4947.71063     Document Type: Article

References (38)

1. Franks S. Polycystic ovary syndrome. N Engl J Med 1995;333:853-61.
2. Fauser BC, Van Heusden AM. Manipulation of human ovarian function: physiological concepts and clinical consequences. Endocr Rev 1997;18:71-106.
3. Baarends WM, Uilenbroek JT, Kramer P, Hoogerbrugge JW, van Leeuwen EC, Themmen A P, et al. Anti-mullerian hormone and antimullerian hormone type II receptor messenger ribonucleic acid expression in rat ovaries during postnatal development, the estrous cycle, and gonadotropin-induced follicle growth. Endocrinology 1995;136:4951-62.
4. Weenen C, Laven JS, Von Bergh AR, Cranfield M, Groome N P, Visser JA, et al. Anti-Mullerian hormone expression pattern in the human ovary: Potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod 2004;10:77-83.
5. Knight PG, Glister C. TGF-beta superfamily members and ovarian follicle development. Reproduction 2006;132:191-206.
6. Carlsson IB, Scott JE, Visser JA, Ritvos O, Themmen A P, Hovatta O. Anti-Mullerian hormone inhibits initiation of growth of human primordial ovarian follicles in vitro. Hum Reprod 2006;21:2223-7.
7. Jonard S, Dewailly D. The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest. Hum Reprod Update 2004;10:107-17.
8. Durlinger AL, Gruijters MJ, Kramer P, Karels B, Kumar TR, Matzuk MM, et al. Anti-mullerian hormone attenuates the effects of FSH on follicle development in the mouse ovary. Endocrinology 2001;142:4891-9.
9. Nelson SM, Yates RW, Lyall H, Jamieson M, Traynor I, Gaudoin M, et al. Anti-Mullerian hormone-based approach to controlled ovarian stimulation for assisted conception. Hum Reprod 2009;24:867-75.
10. Fanchin R, Schonäuer LM, Righini C, Guibourdenche J, Frydman R, Taieb J. Serum anti-Mullerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3. Hum Reprod 2003;18:323-7.
11. Visser JA, de Jong FH, Laven JS, Themmen A P. Anti-Mullerian hormone: A new marker for ovarian function. Reproduction 2006;131:1-9.
12. Lekamge DN, Barry M, Kolo M, Lane M, Gilchrist RB, Tremellen K P. Anti-Müllerian hormone as a predictor of IVF outcome. Reprod Biomed Online 2007;14:602-10.
13. La Marca A, Volpe A. AntiMullerian serum levels during pregnancy. Clin Endocrinol (Oxf) 2006;64:715-6.
14. Bath LE, Wallace WH, Shaw M P, Fitzpatrick C, Anderson RA. Depletion of ovarian reserve in young women after treatment for cancer in childhood: Detection by anti-Mullerian hormone, inhibin B and ovarian ultrasound. Hum Reprod 2003;18:2368-74.
15. Eldar-Geva T, Ben-Chetrit A, Spitz IM, Rabinowitz R, Markowitz E, Mimoni T, et al. Dynamic assays of inhibin B, anti-Mullerian hormone and estradiol following FSH stimulation and ovarian ultrasonography as predictors of IVF outcome. Hum Reprod 2005;20:3178-83.
16. Ebner T, Sommergruber M, Moser M, Shebl O, Schreier-Lechner E, Tews G. Basal level of anti-Mullerian hormone is associated with oocyte quality in stimulated cycles. Hum Reprod 2006;21:2022-6.
17. Chang CL, Wang TH, Horng SG, Wu HM, Wang HS, Soong YK. The concentration of inhibin B in follicular fluid: Relation to oocyte maturation and embryo development. Hum Reprod 2002;17:1724-8.
18. Seifer DB, MacLaughlin DT, Christian B P, Feng B, Shelden RM. Early follicular serum mullerianinhibiting substance levels are associated with ovarian response during assisted reproductive technology cycle. Fertil Steril 2002;77:468-71.
19. Pigny P, Jonard S, Robert Y, Dewailly D. Serum Antimullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91:941-5. (Pubitemid 43357762)
20. Pigny P, Merlen E, Robert Y, Cortet-Rudelli C, Decanter C, Jonard S, et al. Elevated serum level of AMH in patient with PCOS: Relationship to the ovarion follicle excess to the follicular arrest. J Clin Endocrinol Metab 2003;88:5957-62.
21. Laven JS, Mulders AG, Visser JA, Themmen A P, De Jong FH, Fauser BC. Anti-Mullerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab 2004;89:318-23.
22. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Hum Reprod 2004;19:41-7.
23. Gnoth C, Schuring AN, Friol K, Tigges J, Mallmann P, Godehardt E. Relevance of anti-Mullerian hormone measurement in a routine IVF program. Hum Reprod 2008;23:1359-65.
24. Fanchin R, Louafi N, Méndez Lozano DH, Frydman N, Frydman R, Taieb J. Per-follicle measurements indicate that anti-müllerian hormone secretion is modulated by the extent of follicular development and luteinization and may reflect qualitatively the ovarian follicular status. Fertil Steril 2005;84:167-73.
25. Peñarrubia J, Fábregues F, Manau D, Creus M, Casals G, Casamitjana R, et al. Basal and stimulation day 5 anti-Mü llerian hormone serum concentrations as predictors of ovarian response and pregnancy in assisted reproductive technology cycles stimulated with gonadotropin-releasing hormone agonist-gonadotropin treatment. Hum Reprod 2005;20:915-22.
26. La Marca A, Giulini S, Tirelli A, Bertucci E, Marsella T, Xella S, et al. Anti-Mullerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology. Hum Reprod 2007;22:766-71.
27. Hazout A, Bouchard P, Seifer DB, Aussage P, Junca AM, Cohen-Bacrie P. Serum anti-mullerian hormone/mullerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than folliclestimulating hormone, inhibin B, or estradiol. Fertil Steril 2004;82:1323-9.
28. Guerif F, Lemseffer M, Couet ML, Gervereau O, Ract V, Royere D. Serum antimüllerian hormone is not predictive of oocyte quality in vitro fertilization. Ann Endocrinol (Paris) 2009;70:230-4.
29. Jee BC, Ku SY, Suh CS, Kim KC, Lee WD, Kim SH, et al. Serum anti-mullerian hormone and inhibin B levels at ovulation triggering day can predict the number of immature oocytes retrieved in in vitro fertilization cycles. J Korean Med Sci 2008;23:657-61.
30. Gruijters MJ, Visser JA, Durlinger AL, Themmen A P. Anti-Mullerian hormone and its role in ovarian function. Mol Cell Endocrinol 2003;211:85-90.
31. Cupisti S, Dittrich R, Mueller A, Strick R, Stiegler E, Binder H, et al. Correlations between anti-müllerian hormone, inhibin B, and activin A in follicular fluid in IVF/ICSI patients for assessing the maturation and developmental potential of oocytes. Eur J Med Res 2007;12:604-8.
32. Takahashi C, Fujito A, Kazuka M, Sugiyama R, Ito H, Isaka K. Anti-Mullerian hormone substance from follicular fluid is positively associated with success in oocyte fertilization during in vitro fertilization. Fertil Steril 2008;89:586-91.
33. Mashiach R, Amit A, Hasson J, Amzalzg S, Almog B, Ben-Yosef D, et al. Follicular fluid levels of anti-Mullerian hormone as a predictor of oocyte maturation, fertilization rate, and embryonic development in patients with polycystic ovary syndrome. Fertil Steril 2010;93:2299-302.
34. Desforges-Bullet V, Gallo C, Lefebvre C, Pigny P, Dewailly D, Catteau-Jonard S. Increased antimullerian hormone and decreased FSH levels in follicular fluid obtained in women with polycystic ovaries at the time of follicle puncture for in vitro fertilization. Fertil Steril 2009 in press.
35. Fanchin R, Mendez Lozano DH, Frydman N, Gougeon A, Di Clemente N, Frydman R, et al. Anti-Müllerian hormone concentrations in the follicular fluid of the preovulatory follicle are predictive of the implantation potential of the ensuing embryo obtained by in vitro fertilization. J Clin Endocrinol Metab 2007;92:1796-802.
36. Lie Fong S, Baart EB, Martini E, Schipper I, Visser JA, Themmen A P, et al. Anti-Müllerian hormone: A marker for oocyte quantity, oocyte quality and embryo quality? Reprod Biomed Online 2008;16:664-70.
37. Smeenk JM, Sweep FC, Zielhuis GA, Kremer JA, Thomas CM, Braat DD. Antimüllerian hormone predicts ovarian responsiveness, but not embryo quality or pregnancy, after in vitro fertilization or intracyoplasmic sperm injection. Fertil Steril 2007;87:223-6.
38. Eldar-Geva T, Margalioth EJ, Gal M, Ben-Chetrit A, Algur N, Zylber-Haran E, et al. Serum anti-Mullerian hormone levels during controlled ovarian hyperstimulation in women with polycystic ovaries with and without hyperandrogenism. Hum Reprod 2005;20:1814-9.